Skip to main content
Fig. 3 | Human Genomics

Fig. 3

From: Association of lipid-lowering drugs with risk of sarcopenia: a drug target mendelian randomization study and meta-analysis

Fig. 3

Scatter plots depict the SNP effect of genetically proxied LDL-C decrease (x-axis) on the risk of sarcopenia related-traits (y-axis), which indicate that inhibition of HMGCR is related to an increase in appendicular lean mass using LDL-C datasets from Sakaue et al. (a) and GLGC (b). In contrast, inhibition of PCSK9 is significantly associated with a decrease in appendicular lean mass using LDL-C datasets from Sakaue et al. (c) and GLGC (d). Inhibition of HMGCR is associated with a decelerated walking pace using LDL-C datasets from Sakaue et al. (e) and GLGC (f). MR, Mendelian randomization; HMGCR, 3-hydroxy-3-methylglutaryl coenzyme A reductase; PCSK9, proprotein convertase subtilisin/kexin type 9; NPC1L1, Niemann-Pick C1-like 1; LDL-C, low-density lipoprotein cholesterol; GLGC, Global Lipids Genetics Consortium

Back to article page

Human Genomics

ISSN: 1479-7364